These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21039068)

  • 1. NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report.
    Barreiro-de Acosta M; Ouburg S; Morré SA; Crusius JB; Lorenzo A; Potel J; Salvador-Peña A; Domínguez-Muñoz JE
    Rev Esp Enferm Dig; 2010 Oct; 102(10):591-5. PubMed ID: 21039068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of NOD2/CARD15 polymorphisms on response to monoclonal antibody therapy in Crohn's disease: a systematic review and meta-analysis.
    Wang X; Qin L; Cao J; Zhao J
    Curr Med Res Opin; 2016 Dec; 32(12):2007-2012. PubMed ID: 27533749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CARD15/NOD2, CD14 and toll-like 4 receptor gene polymorphisms in Saudi patients with Crohn's Disease.
    Azzam N; Nounou H; Alharbi O; Aljebreen A; Shalaby M
    Int J Mol Sci; 2012; 13(4):4268-4280. PubMed ID: 22605977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease.
    Gutiérrez A; Scharl M; Sempere L; Holler E; Zapater P; Almenta I; González-Navajas JM; Such J; Wiest R; Rogler G; Francés R
    Gut; 2014 Feb; 63(2):272-80. PubMed ID: 23376290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
    Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
    J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.
    Lu C; Waugh A; Bailey RJ; Cherry R; Dieleman LA; Gramlich L; Matic K; Millan M; Kroeker KI; Sadowski D; Teshima CW; Todoruk D; Wong C; Wong K; Fedorak RN
    World J Gastroenterol; 2012 Sep; 18(36):5058-64. PubMed ID: 23049214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population.
    Gazouli M; Mantzaris G; Kotsinas A; Zacharatos P; Papalambros E; Archimandritis A; Ikonomopoulos J; Gorgoulis VG
    World J Gastroenterol; 2005 Feb; 11(5):681-5. PubMed ID: 15655821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common NOD2/CARD15 and TLR4 Polymorphisms Are Associated with Crohn's Disease Phenotypes in Southeastern Brazilians.
    Tolentino YF; Elia PP; Fogaça HS; Carneiro AJ; Zaltman C; Moura-Neto R; Luiz RR; Carvalho Mda G; de Souza HS
    Dig Dis Sci; 2016 Sep; 61(9):2636-47. PubMed ID: 27107867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the NOD2 gene are associated with a specific phenotype and lower anti-tumor necrosis factor trough levels in Crohn's disease.
    Schäffler H; Geiss D; Gittel N; Rohde S; Huth A; Glass Ä; Brandhorst G; Jaster R; Lamprecht G
    J Dig Dis; 2018 Nov; 19(11):678-684. PubMed ID: 30284387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.